Epalrestat

Epalrestat CAS 82159-09-9 is an aldose reductase inhibitor, which can be used to prevent, improve and treat peripheral nerve disorders (numbness and pain) associated with diabetes.

Epalrestat CAS 82159-09-9 is an aldose reductase inhibitor, which plays a role in reversibly inhibiting the aldose reductase from glucose to sorbitol in the polyhydric alcohol metabolism related to the pathogenesis of diabetes complications. It is known that sorbitol can affect the function of nerve cells, and its accumulation in neurons will cause peripheral neuropathy symptoms of diabetes sexual innervating sensorimotor.

Epalrestat CAS 82159-09-9 can be used to prevent, improve and treat peripheral nerve disorders (numbness and pain) complicated by diabetes, diabetes neuropathy, etc. The clinical manifestations are numbness of hands and feet, blurred vision, dry and itchy skin, fatigue, palpitation and sweating. It is an aldose reductase inhibitor that can also reversibly inhibit the aldose reductase from glucose to sorbitol in the polyol metabolism related to the pathogenesis of diabetes complications. It is known that sorbitol can affect the function of nerve cells, and its accumulation in neurons will cause the peripheral neuropathy symptoms of diabetes that controls sensory movement. Abnormal vibration sensation and abnormal heartbeat (showing high glycated hemoglobin value).

Epalrestat CAS 82159-09-9 is a reversible non competitive inhibitor of aldose reductase, with selective inhibitory effects on aldose reductase. Clinical research shows that Epalrestat CAS 82159-09-9 can inhibit the accumulation of sorbitol in erythrocytes of patients with diabetes peripheral neuropathy, and can improve the patients' conscious symptoms and neurological dysfunction compared with the control group. Animal experiments showed that Epalrestat CAS 82159-09-9 could significantly inhibit the accumulation of sorbitol in the sciatic nerve, red blood cells and retina of diabetes model rats, and improve their motor nerve conduction velocity and autonomic nervous function; In terms of neuromorphology, Epalrestat CAS 82159-09-9 can improve axonal flow abnormalities, increase the density of myelinated nerve fibers in the sciatic nerve, the thickness of the myelin sheath of the sural nerve, axon area, and axon cylindricity; In addition, Epalrestat CAS 82159-09-9 can also improve the blood flow of the sciatic nerve in model animals and increase its inositol content.